De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Smaregi Toekomstige groei

Future criteriumcontroles 3/6

Smaregi zal naar verwachting groeien in winst en omzet met respectievelijk 17.4% en 15.5% per jaar. De winst per aandeel zal naar verwachting groeien met 17.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 18.5% zijn.

Belangrijke informatie

17.4%

Groei van de winst

17.4%

Groei van de winst per aandeel

Software winstgroei	21.5%
Inkomstengroei	15.5%
Toekomstig rendement op eigen vermogen	18.5%
Dekking van analisten	Low
Laatst bijgewerkt	12 Sep 2024

Recente toekomstige groei-updates

Recent updates

Capital Investment Trends At Smaregi (TSE:4431) Look Strong

Sep 13

Here's Why We Think Smaregi (TSE:4431) Is Well Worth Watching

Aug 22

Smaregi (TSE:4431) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Jun 27

Is It Time To Consider Buying Smaregi, Inc. (TSE:4431)?

Jun 21

The Returns On Capital At Smaregi (TSE:4431) Don't Inspire Confidence

Mar 26

Winst- en omzetgroeiprognoses

TSE:4431 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (JPY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
4/30/2027	14,000	2,200	N/A	N/A	1
4/30/2026	11,850	1,625	1,250	N/A	2
4/30/2025	10,100	1,375	950	N/A	2
7/31/2024	9,092	1,335	N/A	N/A	N/A
4/30/2024	8,386	1,213	1,346	1,711	N/A
1/31/2024	7,789	1,099	N/A	N/A	N/A
10/31/2023	7,220	946	1,105	1,400	N/A
7/31/2023	6,418	909	N/A	N/A	N/A
4/30/2023	5,914	888	807	986	N/A
1/31/2023	5,546	657	N/A	N/A	N/A
4/30/2022	4,296	557	116	222	N/A
4/30/2018	1,393	216	N/A	N/A	N/A
4/30/2017	938	115	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 4431 ( 17.4% per jaar) ligt boven de spaarquote ( 0.3% ).

Winst versus markt: De winst van 4431 ( 17.4% per jaar) zal naar verwachting sneller groeien dan de JP markt ( 8.7% per jaar).

Hoge groeiwinsten: De winst van 4431 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 4431 ( 15.5% per jaar) zal naar verwachting sneller groeien dan de markt JP ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van 4431 ( 15.5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 4431 zal naar verwachting over 3 jaar laag zijn ( 18.5 %).

Smaregi Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Smaregi, Inc. Revises Non-Consolidated Earning Guidance for the Fiscal Year Ending April 30, 2024

Smaregi, Inc. Provides Earning Guidance for the Fiscal Year Ending April 30, 2024

Smaregi, Inc. Provides Non Consolidated Earnings Guidance for Year Ending April 30, 2023

Smaregi, Inc. Provides Earnings Guidance for Year Ending April 30, 2023

Price target decreased to JP¥2,300

Price target decreased to JP¥3,200

Recent updates

Capital Investment Trends At Smaregi (TSE:4431) Look Strong

Investor sentiment improves as stock rises 16%

Here's Why We Think Smaregi (TSE:4431) Is Well Worth Watching

Now 23% overvalued

Investor sentiment deteriorates as stock falls 16%

Smaregi, Inc. Announces Change in Representative Director

Smaregi, Inc. to Report Q1, 2025 Results on Sep 12, 2024

Smaregi (TSE:4431) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Investor sentiment improves as stock rises 21%

Is It Time To Consider Buying Smaregi, Inc. (TSE:4431)?

Smaregi, Inc., Annual General Meeting, Jul 29, 2024

Now 21% overvalued

Smaregi, Inc. to Report Fiscal Year 2024 Results on Jun 13, 2024

Third quarter 2024 earnings released: EPS: JP¥16.58 (vs JP¥8.86 in 3Q 2023)

The Returns On Capital At Smaregi (TSE:4431) Don't Inspire Confidence

Smaregi, Inc. to Report Q3, 2024 Results on Mar 15, 2024

Smaregi, Inc. Revises Non-Consolidated Earning Guidance for the Fiscal Year Ending April 30, 2024

New major risk - Share price stability

Smaregi, Inc. to Report Q2, 2024 Results on Dec 13, 2023

Smaregi, Inc. to Report Q1, 2024 Results on Sep 13, 2023

Investor sentiment deteriorates as stock falls 16%

Smaregi, Inc. Provides Earning Guidance for the Fiscal Year Ending April 30, 2024

Smaregi, Inc., Annual General Meeting, Jul 27, 2023

Investor sentiment deteriorates as stock falls 15%

Smaregi, Inc. Provides Non Consolidated Earnings Guidance for Year Ending April 30, 2023

Investor sentiment improved over the past week

Smaregi, Inc. to Report Q3, 2023 Results on Mar 15, 2023

Smaregi, Inc. Provides Earnings Guidance for Year Ending April 30, 2023

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Smaregi, Inc. to Report Q2, 2023 Results on Dec 14, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Smaregi, Inc. to Report Q1, 2023 Results on Sep 12, 2022

Smaregi, Inc., Annual General Meeting, Jul 28, 2022

Smaregi, Inc. (TSE:4431) announces an Equity Buyback for 390,000 shares, representing 2% for ¥500 million.

Less than half of directors are independent

Smaregi, Inc. to Report Fiscal Year 2022 Results on Jun 13, 2022

Price target decreased to JP¥2,300

Price target decreased to JP¥3,200

Smaregi, Inc. (TSE:4431) agreed to acquire a 99.9% stake in Royal Gate Inc. from Daiwa House Industry Co.,Ltd. (TSE:1925).

Price target increased to JP¥3,825

Smaregi, Inc. to Report Q3, 2021 Results on Mar 12, 2021

New 90-day high: JP¥5,450

New 90-day high: JP¥5,420

Price target raised to JP¥4,700

Smaregi, Inc. to Report Q2, 2021 Results on Dec 11, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven